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Abstract
Purpose Infliximab, a monoclonal antibody, is approved
for the treatment of inflammatory diseases at doses that
depend on the patient disease population. It was the aim of
this study to evaluate its population pharmacokinetics in
patients with moderately to severely active ulcerative colitis
and characterize patient covariates that affect its disposition
in this population.
Methods Information collected from 482 patients in two
randomized, double-blind, placebo-controlled international
studies were analyzed using NONMEM.
Results A two-compartment, population pharmacokinetic
model described the serum infliximab concentration-time
data. Population pharmacokinetic estimates (typical value ±
standard error), based on the final covariate model, were
clearance (CL: 0.407±0.0103 L/day), apparent volumes of
distribution in the central (V1: 3.29±0.0679 L) and
peripheral (V2: 4.13±0.16 L) compartments, and intercom-
partment clearance (Q: 7.14±0.489 L/day). Infliximab
exhibited interindividual variability for CL and V1 of
37.7% and 22.1%, respectively. Infliximab t1/2 was approx-
imately 14 days. Covariate analysis showed that V1
increased as body weight increased, and CL was higher in
patients who developed antibodies to infliximab. An
additional novel covariate, serum albumin concentration,
was found to be inversely and strongly related to infliximab
clearance in this population.
Conclusions The disposition of infliximab in patients with
moderately to severely active ulcerative colitis, unlike in
rheumatoid arthritis, was not affected by coadministration
of immunomodulators and corticosteroids but was related to
formation of antibodies to infliximab and, notably, to serum
albumin levels.
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Introduction
Infliximab (REMICADE®; Centocor Ortho Biotech, Inc.;
Malvern, PA, USA) is a recombinant chimeric immuno-
globulin (Ig) G1κ monoclonal antibody that neutralizes the
biologic activity of soluble and membrane-bound tumor
necrosis factor alpha (TNF-α). Infliximab is approved for
treatment of rheumatoid arthritis (RA), ankylosing spondy-
litis (AS), psoriatic arthritis (PSA), psoriasis (PSO),
Crohn’s disease (CD), and ulcerative colitis (UC) [1].
Across all indications, a linear relationship was observed
between the dose administered and maximum serum
concentration for adults who received single intravenous
infusions of 3−20 mg/kg. The half-life of infliximab in
several patient populations has been reported as follows:
RA 8−12 days [2]; CD 7.7–9.5 days for single dose [1];
PSO 6.2 −10 days [3]; inflammatory bowel disease (IBD)
with multiple doses 18.5 days for terminal half-life [4]; and
in a recent review, Klotz et al. summarized that infliximab
half-life ranged from 7 to 12 days [5]. The volume of
distribution of infliximab was reported to be 3−6L[ 5].
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DOI 10.1007/s00228-009-0718-4Serum infliximab concentrations influence the response
observed in luminal [6] and fistulizing [7] CD, RA [8], and
PSO [3], but there is a high interindividual variability in
serum infliximab concentrations during treatment with
infliximab. In a previous analysis, we reported the
pharmacokinetics (PK) of infliximab in patients with AS
where certain patients characteristics affecting infliximab
clearance were identified [9]. Similarly, Ternant and
colleagues reported an analysis of infliximab PK in patients
with IBD [4]; however, this analysis included only two
patients with UC. Evidence suggests that therapeutics with
infliximab may vary by disease state. For example, rigorous
clinical development of infliximab has led to the recom-
mendation of different infliximab dosing regimens among
the approved indications. In RA, 3 mg/kg every 8 weeks
(q8w) is the recommended maintenance dose, whereas in
AS, 5 mg/kg q6w is recommended. In CD and UC,
infliximab 5 mg/kg q8w is recommended as maintenance
dose. Despite the common mechanism of action in these
inflammatory diseases, the varying dosing requirements for
optimal efficacy imply that patients and/or disease charac-
teristics may influence the PK of infliximab differently
among patient populations.
Differences in observed efficacy among patient popula-
tions with anti-TNF-α therapy is not limited to infliximab.
Etanercept is effective in both RA and PSO, but not CD
[10, 11] at the dose tested. Some reports have attributed the
lack of efficacy to lower systemic exposure in the CD
patient population compared with RA or PSO populations
after etanercept administration despite evidence that TNF-α
suppression is effective for these disease states [12].
Irrespective of the reason for lack of effect of etanercept
in CD, these observations confirm that patient character-
istics may affect anti-TNF-α agents differently.
Patient characteristics can be very different among thera-
peutic areas; median body weight in RA and PSA in clinical
trials of infliximab populations is greater than in the UC
population. These and other factors may affect differential
drug disposition and efficacy. Thus, it is essential to identify
and understand patient characteristics in the different disease
populations that can impact the PK of an anti-TNF-α agent.
Factors such as development of antibodies to infliximab and
administration of concomitant immunomodulators have been
suggested to be partially responsible for infliximab serum
concentration variability [2]. However, different concomitant
medications are generally used in the different disease
populations. Therefore, it is important to use a large data
pool, when available, to fully identify and accurately quantify
important patient characteristics that may impact infliximab
PK in different indications.
In this study, we report the results of population PK
analysis of infliximab in patients with UC from two double-
blind, placebo-controlled, phase 3 clinical trials. The results
identify a new covariate and quantitatively described all
important covariates that were found to influence the PK
properties of infliximab in this patient population.
Materials and methods
Patients
Active Ulecerative Colitis Trial ACT 1 and ACT 2 were
randomized, double-blinded, placebo-controlled, phase 3
clinical trials conducted globally. A total of 728 patients
were randomized at 62 sites in ACT 1 (N=364) and at 55
sites in ACT 2 (N=364). The institutional review board or
ethics committee at each site approved the protocols, and
all patients provided informed consent.
Study design
The design and conduct of these trials have been reported
previously [13]. Briefly, all patients had an established
diagnosis of UC and moderately to severely active disease
with a Mayo score [14]o f6 −12 points (range 0−12; higher
scores indicate more severe disease activity) despite
concurrent treatment with corticosteroids alone or in
combination with azathioprine or 6-mercaptopurine (ACT
1 and 2) or medications containing 5-aminosalicylates
(ACT 2 only). Patients diagnosed with indeterminate colitis,
Crohn’s disease, or clinical findings suggestive of Crohn’s
disease (i.e., fistula or granulomas on biopsy) were not
enrolled. As previously described, concurrent therapy was
not required at enrollment for patients who could not tolerate
or had had no response to these medications [13]. Doses of
concomitant medications remained constant except for
corticosteroids, which were tapered by 5 mg weekly after
week 8 until a dose of 20 mg/day was reached; thereafter, the
dose was reduced by 2.5 mg weekly until discontinuation.
Patients were randomized equally (1:1:1) to receive intrave-
nous infusions of infliximab at 5 mg/kg or 10 mg/kg, or
placebo at weeks 0, 2, and 6, and then every 8 weeks
through week 22 in ACT 2 or week 46 in ACT 1. Patients
were followed for PK and immune response purposes
through week 42 in ACT 2 and week 54 in ACT 1. The
duration of each infusion was approximately 2 h.
In ACT 1, blood samples for determining infliximab
concentrations were drawn just before and 1 h after the
infusion at weeks 0, 2, 6, 14, and 46 and just before the
infusion at weeks 30 and 38. Additional blood samples for
infliximab concentration determination were drawn at
weeks 8 and 54 (nondosing visits). In ACT 2, blood
samples were drawn just before and 1 h after the infusion at
weeks 0 and 2 and just before the infusion at weeks 6 and
14. Additional blood samples for infliximab concentration
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visits). Serum infliximab concentrations were determined
using a validated enzyme-linked immunosorbent assay [15]
with a lower limit of quantification (LLOQ) of 0.1µg/ml at
a 1:25 dilution. The intra-assay precision, expressed as a
coefficient of variation, ranged from 12.87% to 16.15%,
whereas the interassay precision ranged from 12.39% to
15.94%.
Serum samples analyzed for antibodies to infliximab
were collected before infusions at weeks 0 and 30 in both
studies and at week 42 in ACT 2 and week 54 in ACT 1.
Antibodies to infliximab were determined using an antigen-
bridging enzyme immunoassay [15]. Patients were clas-
sified as positive if antibodies to infliximab were detected
at any visit. If antibodies to infliximab were not detected,
patients were classified as nonpositive. However, many
patients may fall into this category because measurable
concentrations of infliximab were present in serum
samples at the time antibody to infliximab is being tested.
The method is not able to determine whether antibody to
infliximab is present (technically, the test would be
inconclusive). Some patients had neither detectable
infliximab nor antibody to infliximab (negative). For the
purpose of our analysis, patients in the last two categories
were grouped together. Of the 484 patients randomized to
receive infliximab 5 mg/kg or 10 mg/kg, 482 received at
least one infusion and had appropriate serum infliximab
concentration data.
Infliximab concentration data
A total of 96 (2.2%) incongruous or obviously erroneous
sample concentrations [most of these were trailing LLOQs
(58 of 96)] and were subsequently excluded from the
analyses. If, for example, an immediate preinfusion
concentration was greater than the immediate postinfusion
concentration (usually due to pre-/postinfusion blood-
collection sample-tube switch), both data points were
excluded. Also, when there were multiple adjacent inflix-
imab concentrations less than LLOQ in a profile within a
single dose interval, the first LLOQ was retained while the
other (trailing) LLOQ(s) was excluded from the analysis.
One of the 484 patients had an anomalous concentration
profile that could not be reasonably accounted for;
therefore, this patient’s data were excluded from the
analysis. After development of an acceptable structural
model, potential outliers that had weighted residuals
(WRES) >5.0 were excluded from the final analysis.
Covariate data
The baseline covariate value was defined as the last
recorded value before the first infliximab dose. For missing
covariate baseline values, median values were imputed for
continuous covariates, and the category with the highest
proportion of patients was imputed for categorical covar-
iates. Sensitivity analysis was performed where appropriate
to evaluate the impact of imputed covariate data. Demo-
graphic covariates for the population PK data set were age
(year), body weight (kg), sex, and race (i.e., Caucasian,
African American, Asian, and others). Blood chemistry
covariates were biomarkers of kidney function [serum
creatinine (mg/dl), estimated creatinine clearance (CRCL,
ml/min) [16], blood urea nitrogen (BUN, mg/dl)], liver
function [aspartate aminotransferase (AST, U/L), alanine
aminotransferase (ALT, U/L), alkaline phosphatase (U/L),
bilirubin (mg/dl)], clinical chemistry analytes [C-reactive
protein (mg/dl), albumin (g/dl), total protein (g/dl)], and
hematology parameters [hemoglobin (g/dl), hematocrit (%),
white blood cell count (×10
9cells/L), platelets (×10
9cells/L),
and lymphocytes (×10
9cells/L)]. Additional covariates were
concomitant immunomodulator use (azathioprine, 6-
mercaptopurine, and/or corticosteroids) and Mayo score at
baseline and development of antibodies to infliximab during
the trials (i.e., positive anti-infliximab antibody status).
Infliximab concentration-time data were analyzed using
NONMEM (Version VI, Level 1; ICON Development
Solutions, Ellicott City, MD, USA). The programs were
run on Microsoft Windows 2000 Professional operating
system on an Intel Pentium M processor PC. NONMEM and
bootstrap procedures were executed using Wings for NON-
MEM, version 611 [17]. Xpose4 (Release 6) was used for
data visualization and other model diagnostics [18].
Population pharmacokinetic model development
Preliminary data review included the following: checking
for potential outlying data points, covariate distribution,
scatter plots of concentration versus time, and summary
statistics of patient characteristics. Data were analyzed
using the first-order conditional estimation method with
interaction (FOCE-I) in NONMEM. One, two, and three-
compartment models with zero-order infusion and first-
order elimination were explored during the structural model
development. Interindividual variability (IIV) with
corresponding correlated random effects (i.e., a full vari-
ance−covariance matrix) was assumed in all PK parameters.
Individual values of PK parameters were assumed to follow
a log-normal distribution that was implemented as follows:
Pi ¼ Θ   exp hi ðÞ
where Pi is the parameter of interest in the ith patient, Θ is
the estimate of the population mean or the typical value of
the parameter, and ηi is the deviation from the population
mean for the ith patient under the assumption that ηi is an
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variance of ω
2 ( i.e., η∼N(0,ω
2). Proportional, additive, or
combined-error models were examined to assess the
residual variability. For example, a combined additive and
proportional-error model was implemented as follows:
Yij ¼ Cij 1 þ "1ij

þ "2ij
where Yij is the jth observed concentration for the ith
patient, Cij is the corresponding predicted concentration;
ε1ij and ε2ij are the residual errors for the proportional and
additive components of the model with means of zero and
variances of σ1
2 and σ2
2, respectively (i.e., ε∼N(0, σ
2 ).
The Akaike information Criteria (AIC) was employed to
discriminate nonnested structural models during the struc-
tural model exploratory stage and was calculated from the
NONMEM objective function value (OFV), as follows:
AIC ¼ OFV þ 2   p
where p represents the number of parameters in the model
being estimated.
In general, goodness of fit for a given model was
assessed by plots of observed infliximab concentrations
(DV) versus population-predicted (PRED) and individual-
predicted concentrations (IPRED) (i.e., DV vs. PRED and
DV vs. IPRED, respectively). The residual error compo-
nents of models were assessed via scatter plots of weighted
residuals (WRES) and conditional weighted residuals
(CWRES) versus predicted data (i.e., WRES or CWRES
vs. PRED, respectively). Plots of absolute individual
weighted residuals (|IWRES|) versus IPRED were also
explored. Smooth nonparametric trend curves [locally
weighted scatter plot smoother (LOESS)] were included
as appropriate to illustrate underlying patterns. Magnitude
of random error was also considered in model discrimina-
tion. Changes in IIVand residual variability were compared
when a new covariate was added to a starting model to
explore possible inclusion of such a covariate. In general, a
model that converged with a successful covariance step was
considered for further analysis, whereas one with any
correlation of parameter estimates >0.95 was rejected as a
preliminary model for subsequent model development.
Covariate model
Covariate screening
Empirical Bayes estimates (EBEs) were generated from the
estimation step in NONMEM. Trends between covariates and
PK parameters were graphically examined, as described
previously [9]. However, due to potential drawbacks associ-
ated with EBE graphical exploration (e.g., subjectiveness and
parameter shrinkage) [19], candidate covariates were further
tested directly in NONMEM to verify and quantify their
relationship with PK parameters. The effects of continuous
covariates such as weight on CL, volumes of distribution in
the central (V1) or peripheral (V2) compartments were
generally assessed using a function as expressed below:
Pj ¼ Ppop  
Covj
Covm
 Θcov
where Pj is the model predicted value of a PK parameter P in
the jth patient for a given covariate value, Covj,a n dΘcov
represents a scaling factor for the influence of that covariate.
Covm represents the median value of the covariate in the
population. Ppop is thus the typical value of parameter P
corresponding to the median value of the covariate of interest
in the population. Categorical covariates such as binary
covariates (e.g., gender or use of concomitant medications)
were incorporated into the model as index variables and
modeled as expressed below:
Pj ¼ Ppop   1 þ Covi   Θcov ðÞ
where Covi is the numeric index value of the covariate
(typically 0 for the reference category or 1 for the
comparative category), Pj is the model predicted value of
the parameter for the jth patient, Ppop represents the value of
the parameter for the reference covariate value (i.e., when
Covi is 0) and Θcov represents a multiplicative factor for the
influence of that covariate such that if Θcov is less than 0, the
net effect is a decrease in the typical value, and if Θcov is
greater than 0, the net effect is an increase in the typical
value of the parameter.
Stepwise covariate modeling
Stepwise forward addition/backward deletion of covariate
modeling approach was adopted during covariate selection.
Covariates that individually influenced PK parameters were
added in descending order of magnitude with regard to
reduction of OFV. The log-likelihood ratio test was the
primary criterion used to determine the appropriateness of
covariate selection. The full model for covariate effects was
built using a stepwise inclusion approach based on a p
value of 0.05, which corresponds to a difference in
NONMEM objective function >3.84 (χ-square distribution,
1 degree of freedom). Once a covariate was included in the
model, the resulting model became the new model and the
remaining covariates were individually retested. This
iterative process continued until no additional covariates
led to further significant reduction in OFV; therefore, this
model was designated the full model.
Following the identification of the full model, model
reduction based on backward deletion was implemented
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The statistical significance of each covariate−parameter
relationship was individually assessed during the stepwise
deletion phase at the p<0.001 level, i.e., only covariates
associated with an increase of at least 10.83 in OFV were
retained in the model. This stricter criterion was applied due
to the multiple comparisons made during the forward
addition covariate modeling procedure. In this procedure,
a particular covariate parameter in the full model was fixed
to its null value, and the model was run to obtain a new
OFV. The covariate was then returned to the model and the
next covariate parameter was tested in similar manner. This
scenario was repeated for each covariate. The covariate
with the smallest change in OFV (∆OFV) not meeting the
prespecified criteria above was then removed from the
model. This cycle was repeated in a stepwise fashion until
only those covariates producing significant ∆OFV remained
in the model. The resulting model was regarded as the final
model that adequately described the population PK of
infliximab in this population of patients with UC.
Population pharmacokinetic model qualification
Bootstrap resampling technique was applied as an internal
validation tool to assess the stability of the final parameter
estimates and to confirm the robustness of the final model
[20]. Two thousand bootstrap replicates were generated by
randomly resampling the original data set with replacement.
The base and final models were fitted to the replicate data
sets. The median values and 95% confidence intervals (CIs)
(i.e., 2.5th and 97.5th percentiles) of these 2,000 bootstrap
replicates were compared with the point estimates from the
original data set. Model stability was also assessed by
calculating the condition number (the ratio of the largest to
smallest eigenvalue of the covariance matrix) of the final
model, with a value of 1,000 being indicative of ill-
conditioning. The extent of η and ε-shrinkage in the PK
parameters was also computed according to the following:
hshrinkage ¼ 1  
SD hEBE;P

wP
"shrinkage ¼ 1   SD IWRES ðÞ
where SD(ηEBE,p) is the standard deviation of the empirical
Bayes estimates of random effect (η), ωp is the population
model estimate of the SD in η, and SD(IWRES) is the
standard deviation of the individual weighted residuals.
External model evaluation
The external model validation approaches described by
Brendel and colleagues were employed [21]. The first
approach involved a direct comparison of the population
model parameters obtained from the ACT 1 data set with
those obtained from the ACT 2 data set. The procedure for
the comparison without simulation involved developing
base models for ACT 1 and ACT 2 data and comparing the
computed PK parameters of ACT 1 to those of ACT 2
using the Wald statistic [21]. Additionally, a posterior
predictive check involving Monte Carlo simulations was
performed. In this procedure, parameters obtained from
ACT 1 population PK model were used to simulate 1,000
data sets based on the ACT 2 study design. The empirical
distribution of the parameters obtained from the simulated
data sets was then compared with the population PK
parameters estimated from the ACT 2 data set itself.
Differences between parameters from the simulated and
original data sets were compared using two-sided statistical
tests at the 0.05 level of significance, as described by
Brendel and colleagues [21].
Results
ACT 1 base model
A two-compartment structural model adequately described
the concentration-time profiles of infliximab. The mean
population parameter values and the IIVs for the structural
model are provided in Table 1. All mean population PK
parameter estimates fell within the 95% CI of bootstrap
resampling of 2,000 replicates simulated.
ACT 2 base model
Similarly, in ACT 2, a two-compartment structural model
adequately described the concentration-time profiles of
infliximab. Population parameter values for the structural
model are provided in Table 1.
Validation of ACT 1 model using ACT 2 data
The most appropriate structural model was determined to
be the same for each of the studies after internal validation
for each study. With the exception of Q, no significant
differences were found between the parameters estimated
for the ACT 1 and ACT 2 models (Table 1). The value for
Q is usually difficult to determine accurately; this result
may very likely be due to the sparseness of data in ACT 2.
External validation of population PK parameters based on
the posterior predictive check involving Monte Carlo
simulations of ACT 2 design from ACT 1 did not show
any apparent bias. Similarly, histograms of the predictive
distribution of simulated population parameters were gener-
ally consistent between simulated and actual data (data not
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analyses used the ACT 1 and ACT 2 combined data set.
Combined data from ACT 1 and ACT 2
In ACT 1 and ACT 2 combined, 483 patients were treated
with infliximab and available in the population PK data
set; however, data for one patient were excluded because
the concentration-time profile was anomalous. A total of
4,145 of 4,310 concentration data points from 482 patients
were evaluable and included in the final analysis. Thus,
approximately 4% of data were excluded, primarily
attributable to trailing LLOQ values. Overall, an average
of approximately 8.6 concentration data points per patient
was included in the base model for population PK
analysis.
Covariates
The summary of covariates in the population PK data set is
provided in Table 2. At baseline, a majority of patients
received aminosalicylates.
Base model for combined ACT 1 and ACT 2 data
The base model was selected from among structural
models tested based on AIC values and goodness-of-fit
plots. A two-compartment model with first-order elimina-
tion was preferable to a one- or three-compartment model.
The two-compartment model had an AIC value of 27046,
whereas the one- and three-compartment models had AIC
values of 28006 and 27086, respectively. The two-
compartment model was parameterized for CL, V1,V 2,
and Q. Models using a full omega variance−covariance
block matrix on all structural parameters or a diagonal
variance structure on all or some parameters did not result
in acceptable convergence. However, a model with a full
omega variance−covariance matrix on CL and V1,w h i c h
assumed similar variance and covariance block for V2 and
Q, was successfully implemented. The model with
combined proportional and additive residual errors had
ΔOFVof −215 when compared with the model with only
proportional error. Similarly, the model implementing a
combined residual error was superior to that with an
additive residual error only (ΔOFV of −6002). Thus, a
combined proportional and additive model was deemed
best for describing residual error based on goodness-of-fit
plots and lower OFV. The PK parameter estimates ±
standard error (SE) obtained from the base model are
s h o w ni nT a b l e3. The terminal half-life for infliximab was
about 14 days. Table 3 summarizes the base model
parameter estimates and 95% CIs obtained from the
bootstrap.
Goodness-of-fit plots obtained from the base model
show that the population and individual predicted values
visually match the measured values (Fig. 1). Additionally,
residual error plots showed no systematic deviation over
time. The mean (± SD) of the CWRES was close to zero
[0.04 (±0.94)], indicating that the model parameters
satisfactorily described the data. Histograms of WRES
and CWRES appeared approximately normal, with no
consistent systematic residual trends.
EBE shrinkage
The model parameters had fairly moderate levels of η-
shrinkage for CL (10.5%), V1 (26.9%), and V2 (29.2%)
apart from Q (58.9%), suggesting some caution in
interpreting covariate relationship based on the EBEs of
Q. The magnitude of ε-shrinkage was also low (8.1%);
thus, diagnostic plots of IPRED are expected to reliably
detect any structural model anomalies, if present.
Covariate models
Univariate models
Table 4 shows the impact of some of the covariates on the
OFV of population PK model when each covariate was
tested on each of the PK parameters.
Hyperparameter ACT 1 ACT 2 P value
Estimate RSE (%) Estimate RSE (%)
CL (L/day) 0.378 2.9 0.388 3.0 0.529
V1(L) 3.17 2.0 2.99 3.3 0.129
V2(L) 4.39 4.8 4.02 6.0 0.246
Q(L/day) 6.22 8.2 10.0 8.4 <0.001
ωCL
2 0.209 10.4 0.155 11.2 0.052
ωV1
2 0.0674 14.7 0.0938 22.8 0.254
σadd 0.0424 6.3 0.0407 3.7 0.582
σprop 0.399 3.5 0.411 3.1 0.524
Table 1 Population pharmaco-
kinetic parameter estimates of
infliximab (base models)
CL clearance, V1 volume of
distribution in the central com-
partment, V2 volume of distri-
bution in the peripheral
compartment, Q intercompart-
mental clearance, RSE relative
standard error, ACT Active
Ulcerative Colitis Trial.
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Demography Kidney function
Age, years Serum creatinine (mg/dl)
Mean ± SD 41.2±13.9 Number 477
Median (min, max) 40 (18, 81) Mean ± SD 0.9±0.2
Gender, n (%) Median (min, max) 0.8 (0.3, 3.1)
Male 293 (60.8) Creatinine clearance (ml/min)
Female 189 (39.2) Number 477
Race, n (%) Mean ± SD 122.4±35.4
Caucasian 454 (94.2) Median (min, max) 118.4 (35.7, 325.9)
Non-Caucasian 28 (5.8) Blood urea nitrogen (mg/dl)
Weight, kg Number 477
Mean ± SD 78.8±18.4 Mean ± SD 13.1±4.4
Median (min, max) 77 (40, 177.3) Median (min, max) 12 (5, 31)
Concomitant UC medication, n (%) Clinical chemistry
Baseline AZA/6-MP 227 (47.1) Albumin (g/dl) 477
Baseline corticosteroid 268 (55.6) Number
Baseline 5-ASA 350 (72.6) Mean ± SD 4.1±0.4
Antibodies to infliximab, n (%) Median (min, max) 4.1 (2.4, 5.2)
Positive 33 (6.8) Total protein (g/dl)
Nonpositive 385 (79.9) Number 477
Missing 64 (13.3) Mean ± SD 7.2±0.5
Disease activity Median (min, max) 7.2 (5.6, 9.5)
Mayo score 8.4±1.6 Hematology
Mean ± SD Hemoglobin (g/dl) 472
Median (min, max) 8 (4, 12) Number
C-reactive protein (mg/dl) Mean ± SD 12.9±1.7
Number 479 Median (min, max) 13.1 (7.8, 17.6)
Mean ± SD 1.4±2.2 Hematocrit (%)
Median (min, max) 0.8 (0.2, 22.7) Number 460
Mean ± SD 38.8±4.8
Median (min, max) 38.8 (26.1, 52.7)
Liver function Hematology (cont.)
Alkaline phosphatase (IU/L) Platelets (×10
9/L)
Number 477 Number 465
Mean ± SD 77.3±33.3 Mean ± SD 338.6±105.0
Median (min, max) 72 (25, 421) Median (min, max) 320.5 (103, 773)
ALT (IU/L) White blood cell counts (×10
9/L)
Number 477 Number 449
Mean ± SD 21.7±16.0 Mean ± SD 8.4±3.2
Median (min, max) 17 (5, 180) Median (min, max) 7.8 (2.3, 20.9)
AST (IU/L) Lymphocytes (×10
9/L)
Number 477 Number 459
Mean ± SD 19.6±9.9 Mean ± SD 1.5±0.8
Median (min, max) 18 (5, 98) Median (min, max) 1.3 (0.2, 5.7)
Total Bilirubin (mg/dL)
Number 477
Mean ± SD 0.5±0.5
Median (min, max) 0.4 (0.1, 7.5)
Table 2 Summary of demo-
graphic and clinical character-
istics; patients included in the
population pharmacokinetic
analysis (N=482)
Min minimum, Max maximum,
SD standard deviation, UC ul-
cerative collitis, AZA azathio-
prine, 6-MP 6-mercaptopurine,
5-ASA 5-aminosalicylic acid,
ALT alanine transaminase,AST
aspartate transaminase
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Considering the information from the univariate models and
specified ΔOFV criterion (i.e., ≥ 3.84 at p≤0.05, one
degree of freedom), the most significant covariates to CL
were CRP levels, antibodies to infliximab (ATI) status,
albumin levels, and sex; to V1 were body weight and sex;
and to V2 was body weight (Table 4). A full model was
constructed with these covariates using the forward addition
and backward deletion approach. This resulted in a final
model that consisted of a two-compartment model with
first-order elimination, with ATI status, baseline albumin,
and sex influencing CL; and body weight and sex
influencing V1. All parameters in the final model including
the coefficients or scaling factor for the covariate effects
and the random effects were all estimated with fairly good
precision. Inclusion of covariates explained some of the
random IIVof the population parameters in the final model
for CL and V1. The equations for the final model are as
follows:
CL ¼ 0:407  
ALB
4:1
  1:54
  1:471 ðÞ
ATI   0:764 ðÞ
SEX
V1 ¼ 3:29  
WGT
77
 0:538
  0:863 ðÞ
SEX
Q ¼ 7:14
V2 ¼ 4:13
where ATI status=1 for patients who tested positive and 0
for patients who had non-positive results, and sex=1 for
females and 0 for males.
Parameter NONMEM Bootstrap
a
Estimate % RSE Median 95% CI
Base model
CL (L/day) 0.384 2.3 0.383 0.366, 0.401
V1 (L) 3.09 2.9 3.1 2.83, 3.38
V2 (L) 4.19 4.7 4.18 3.68, 4.62
Q (L/day) 7.50 10.6 7.47 4.09, 10.6
IIV
IIV on CL (%) 42.80 7.8 42.66 39.50, 46.15
IIV on V1 (%) 27.40 13.1 27.24 23.34, 31.37
IIV on V2 (%) ––
IIV on Q (%) ––
Residual variability
Proportional error (%) 40.20 2.4 40.20 38.20, 42.20
Additive error, (µg/ml) 0.0415 7.6 0.0418 0.0369, 0.0502
Final model
CL (L/day) 0.407 2.5 0.406 0.388, 0.427
V1 (L) 3.29 2.1 3.28 3.02, 3.58
V2 (L) 4.13 3.9 4.12 3.65, 4.57
Q (L/day) 7.14 6.8 7.11 3.67, 10.10
ΘALBCL (Scaling factor of Albumin on CL) −1.54 12.6 −1.56 −1.94, −1.17
ΘATICL (Factor of ATI on CL) 0.471 22.5 0.480 0.28, 0.831
ΘSEXCL (Factor of Sex on CL) −0.236 11.9 −0.236 −0.291, −0.181
ΘWGTV1 (Scaling factor of body weight on V1) 0.538 13.5 0.544 0.394, 0.700
ΘSEXV1 (Factor of sex on V1) −0.137 23.2 −0.136 −0.197, −0.072
IIV
IIV for CL (%) 37.68 8.5 37.55 34.50, 40.99
IIV for V1 (%) 22.11 16.6 21.84 17.97, 25.85
IIV for V2 (%) ––
IIV for Q (%) ––
Residual variability
Proportional error (%) 40.30 2.6 40.30 38.30, 42.20
Additive error (µg/ml) 0.0413 3.5 0.0415 0.0368, 0.0497
Table 3 Population pharmaco-
kinetic parameter estimates for
the ACT 1 and ACT 2 studies
(base model and final model)
CL clearance,V1 volume of dis-
tribution in the central compart-
ment, V2 volume of distribution
in the peripheral compartment,
Q intercompartmental clearance,
IIV interindividual variability,
RSE relative standard error,
ACT Active Ulcerative Colitis
Trial. CI confidence interval
aCalculated from 2,000
bootstrap data sets
1218 Eur J Clin Pharmacol (2009) 65:1211–1228Table 3 presents a summary of the parameter estimates
(with associated NONMEM SE) for the final model. The
95% CI obtained by the bootstrap technique are also
included. Figure 2 presents the goodness-of-fit plots for
the final model. There was very little systematic bias in
CWRES where values were centered at approximately 0
with a ± SD of ± 0.96, thus approximating a normal
distribution.
Relationship of covariates and model parameters
Effect of body weight
Body weight was the most significant covariate on V1.
Median body weight in this population was 77 kg (range
40–177 kg). Figures 3a and b show scatter plots of the
EBEs of V1 and CL versus body weight, respectively.
Scatter plots comparing the random effect of V1 (ETA2)
and body weight in the base model (Fig. 3c) and final
model (Fig. 3d) are also illustrated. The variability due to
body weight was corrected for in the final model, as shown
by reduced ETA2 values and loss of the observed base
model trend. The effect of body weight on CL was not
statistically significant (Table 4).
Effect of albumin
Lower albumin levels appear to predict higher infliximab
clearance (Fig. 4a). The relationship between random
effect of CL (ETA1) and serum albumin concentrations
in the base model and final model are shown in Fig. 4b
and c, respectively, where corrections are evident in the
final model for the variability due to baseline albumin
concentration.
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Fig. 1 Goodness-of-fit plots for the base model. Dashed lines represent the locally weighted smoothing (LOESS) of the data
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Thirty-three patients in ACT 1 and 2 were positive for
antibodies to infliximab through week 42 and week 54,
respectively, and were included in the population PK
model. These results show that mean CL was 47.1% higher
for patients positive for antibodies to infliximab compared
with those who were nonpositive. Figure 5a shows a box
plot of CL versus antibody to infliximab status in the base
model. Figure 5b (base model) and c (final model)
compares the relationship of ETA1 versus antibody to
infliximab status; the final model significantly corrected the
base model trend.
Effect of sex
Sex was evaluated as a potential covariate on both CL and
V1 (Fig. 6a and b, respectively). Results of covariate
modeling showed that CL was about 33% lower in women,
and V1 was 16% lower than in men.
Figures 6c (base model) and d (final model) compare
ETA1 and sex and show that the final model significantly
corrected the base model trend. Figures 6e (base model)
and f (final model) compare ETA2 and sex, and show that
the final model corrected some of the base model V1
variability.
Effect of concomitant medications
Concomitant immunomodulators azathioprine and 6-MP did
not significantly impact infliximab PK. This is an important
observation because concomitant immunomodulators has
been shown to affect the PK of infliximab in other
therapeutic indication such as RA. Corticosteroid use at
baseline had only slight effects on CL and V1, which were
not strong enough to warrant their inclusion in the model.
Influence analyses, sensitivity analyses, and model stability
Examination of the EBEs showed that two patients had
suspiciously high CL values compared with the majority of
patients. Further investigation showed that factors associated
with high CL (in the final model) were present in these
patients (i.e., development of antibodies to infliximab or low
baseline albumin concentrations). Sensitivity analyses con-
firmed the robustness of the base and final models. The base
model was rerun after excluding LLOQ values to assess the
effect of the imputation method used to handle these values
in the modeling process and again eliminating outliers (data
excluded because of high weighted residuals >5). Parameter
estimates obtained following the modified analysis did not
differ significantly from those of the original analysis,
although, as expected, estimates of variability were greater
when the outliers were retained and covariate modeling
became unstable leading to nonconvergence at the covar-
iate modeling stage. Because prior analyses showed that
the CL of infliximab varied significantly between patients
who tested positive for ATI and those who did not, a
sensitivity analysis was performed to determine whether
there were differences in IIV by allowing the IIV on
clearance to vary between the two subpopulations. The
results showed that the IIV for clearance in patients who
were positive for ATI was 40.7% and that for those who
did not test positive for ATI was 41.2%. Thus, the IIV for
infliximab clearance remained similar between these two
subgroups and compare very well with that of the
combined population (42.8%). Therefore, a combined
analysis was deemed satisfactory.
The statistical distributions of the parameter estimates
obtained from the bootstrap analyses were symmetrical
around the mean and appeared to follow a normal
distribution. Median values of the parameters estimated
from the bootstrap analyses were in good agreement with
the NONMEM point estimates, and the 95% CIs were
narrow, indicating acceptable precision (Table 3). The
significance of the included covariates was further sup-
ported by the bootstrap analyses, as none of the 95% CIs
for the covariate effects included zero. The condition
numbers of the base and final models were 22.2 and 32.5,
respectively, indicative of each model’s stability. Finally, an
overlay of individual Bayesian estimated PK parameter
predicted curve on the raw data as a visual predictive check
for representative subjects in the study (Fig. 7) shows that
the models adequately fit the observed data.
Table 4 Univariate analyses of selected covariates
Covariate tested OFV ΔOFV P value
Base model 27027.7 NA NA
Weight on CL 27026.1 −1.6 0.206
WBC on CL 27022.2 −5.5 0.019
Sex on CL 27020.8 −6.9 0.009
Mayo score on CL 27017.6 −10.1 0.001
Age on CL 27017.3 −10.4 0.001
Weight on V2 27014.5 −13.2 <0.001
CRP on CL 27010.7 −17 <0.001
ATI on CL 27001.4 −26.3 <0.001
Sex on V1 26992.0 −35.7 <0.001
Albumin on CL 26968.4 −59.3 <0.001
Weight on V1 26950.2 −77.5 <0.001
OFV objective function value, ΔOFV change in objective function
value, CL clearance, WBC white blood cell count, V1 volume of
distribution for the central compartment, V2 volume of distribution for
the peripheral compartment, CRP C-reactive protein, ATI antibodies to
infliximab.
1220 Eur J Clin Pharmacol (2009) 65:1211–1228Discussion
The availability of two randomized clinical trials in the
same patient population allowed a thoroughly developed
population PK analysis of infliximab in patients with UC. A
two-compartment PK model provided reliable PK parame-
ter and covariate effect estimation for infliximab.
V1 was estimated to be 3.29 L for a 77-kg (the median
body weight for this data set) individual. This is similar to
that obtained in the ankylosing spondylitis patient popula-
tion [9]. Infliximab steady-state volume of distribution
(Vss) estimated to be 7.71 L for a 77-kg patient is slightly
higher than the volume of the vascular system (5 L in a 70-
kg individual). This suggests that infliximab is primarily
distributed into the vascular system. These findings are
consistent with the known distribution of endogenous IgG
and some other monoclonal antibody therapies [22, 23]. In
previous PK analyses of infliximab in adults administered
single intravenous infusions of 3−20 mg/kg, a linear
relationship between the dose administered and the maxi-
mum serum concentration was observed. The reported Vss
indicated that infliximab was distributed primarily within
the vascular compartment [24], similar to the finding in this
population PK analysis.
In our population PK analysis, the median half-life
computed from the post hoc population PK parameters was
approximately 14 days, with an interquartile range of 10.4–
17.8 days. This value is comparable with those reported
previously for infliximab [25] and for some anti-TNF-α
monoclonal antibody therapies [26, 27]. However, between
UC and AS populations, Q values (7.14 L/day and 1.72 L/
day in UC and AS, respectively) differ. Also, CL (0.407 and
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Fig. 2 Goodness-of-fit plots for the final model. Dashed lines represent the locally weighted smoothing (LOESS) of the data
Eur J Clin Pharmacol (2009) 65:1211–1228 12210.273) appears to be different between the two populations
[9]. Furthermore,therelativestandarderrorsforQreportedby
Xuandcolleagueswas higherthanthatobtainedinthe current
analyses (27.9% vs 6.8%). In both analyses, the Q term is the
least precisely estimated PK parameter. As discussed previ-
ously [9], generally, accurate assessment of intercompart-
mental clearance was difficult due to the limited sampling
scheme in these late-phase clinical trials (in many instances,
only preinfusion and postinfusion blood sample per dose
were drawn, and on several occasions, only a postinfusion
blood sample was drawn). This did not permit full
characterization of the distribution phase.
The final population PK model contained four cova-
riates: body weight, albumin, immune response status, and
sex. It is apparent from the final model that body size is an
important determinant of infliximab exposure. Body weight
influences V1 (with a power factor of 0.54) but not CL. A
limitation in this analysis to exploring a variety of body size
parameters was the absence of patient height data. This
prevented a precise computation of body-size parameters
such as body mass index, lean body weight, or body surface
area. However, these body-size parameters are usually
highly correlated with body weight. Thus, it was reasonable
to limit the interpretation of the current analyses to body
weight. Similar to our observation, previous analyses also
showed that body surface area or body weight are
covariates of V1, although the coefficients varied for these
patient populations [4, 9]. The increase in infliximab V1 as
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1222 Eur J Clin Pharmacol (2009) 65:1211–1228patient body weight increases is expected because larger
body weight is associated with larger blood volume.
Thus, a body weight-adjusted dosing (as is approved for
infliximab) is necessary to allow equivalent exposure
among all patients to mitigate a possible weight-related
influence of infliximab exposure.
Development of antibodies to infliximab is a factor
known to increase infliximab clearance [9]. The interaction
of antibodies to infliximab with circulating infliximab may
form complexes that clear more rapidly than infliximab
alone. Increased CL in the presence of antibodies to
infliximab is reconfirmed in this analysis, where an
increased CL of approximately 47% was estimated for
patients who developed antibodies to infliximab.
In earlier studies, patients’ sex has been identified as a
potential covariate influencing the PK of some other
monoclonal antibodies [4, 28, 29]. In this study, patients’
sex was associated with both infliximab CL and V1. As the
effect of sex on CL and V1 was directionally consistent
(i.e., male patients on average had higher CL and V1), the
overall effect of sex on infliximab exposure is partially
negated. In addition to sex, body weight, and development
of ATI—covariates that influence infliximab PK parameters
in other inflammatory diseases—this analyses identifies
serum albumin concentration as a novel major covariate of
infliximab PK parameters in patients with UC. Patients with
higher baseline serum albumin concentrations were associ-
ated with lower infliximab CL compared with those with
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Eur J Clin Pharmacol (2009) 65:1211–1228 1223lower albumin concentration. Considering the interquartile
range (3.8 and 4.3 mg/dl) of baseline albumin levels in this
population, and keeping all other covariates at the popula-
tion mean values, the model predicts a 19.1% infliximab
CL increase. Higher albumin levels were associated with
lower infliximab CL and subsequently a longer infliximab
half-life. To our knowledge, this is the first observation of
an association between infliximab CL and serum albumin
concentration. Albumin, endogenous immunoglobulins,
and monoclonal antibody drugs such as infliximab are
protected from catabolism by the neonatal Fc receptor
(FcRn). The FcRn facilitates IgG and albumin homeostasis
by recycling them across cell membranes back to the
central circulatory system [30]. Thus, a higher albumin
concentration could be an indicator of an increased number
of FcRn and related reduced infliximab elimination. Thus,
the association of serum albumin concentrations with
infliximab disposition may be explained by the involve-
ment of FcRn in the conservation of both albumin and
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Eur J Clin Pharmacol (2009) 65:1211–1228 1225infliximab. It may be of clinical utility, especially that the
baseline value, which is easily obtainable after a routine
assay, can be used as one of the predictors of expected
patient disposition of infliximab in the clinical setting. This
is unlike testing positive to antibody to infliximab, a
predictor that is only available after infliximab dose
administration and elimination of infliximab from the
blood.
Immunomodulators (6-MP, azathioprine) and cortico-
steroids commonly coadministered with infliximab in
patients with UC were not significantly associated with
infliximab PK parameter variability in this analysis. This
differs from previous reports where coadministration of
methotrexate (an immunomodulator commonly adminis-
tered with infliximab) in patients with RA were shown to
clearly enhance infliximab exposure [5]. The reason for this
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1226 Eur J Clin Pharmacol (2009) 65:1211–1228disparity is unknown, but our observation is similar to that
in another report that showed a lack of effect of several
drugs, including immunomodulators, on infliximab PK
parameters in ankylosis spondylitis patients [9]. These
observations demonstrate the need to determine the PK
properties of infliximab in different diseases or therapeutic
settings. This is especially so because infliximab is very
widely used and is indicated for several disease conditions
and may be handled differently by patients in those
therapeutic areas. In addition, unlike other small-molecule
drugs, its disposition may not be predictable by markers
of liver and kidney functions (such as ALT, AST and
CRCL).
A population PK model for infliximab in patients with
moderately to severely active UC identified body weight,
albumin, antibody-to-infliximab positivity, and sex as key
covariates influencing infliximab PK. Body-weight-
adjusted dosing as recommended for infliximab in its
label reduced possible gross variability in infliximab
exposure that could arise by the potential influence of
body weight on the volume of distribution of infliximab.
Serum albumin concentration is identified, for the first
time, as a covariate of infliximab disposition. Its amena-
bility to routine measurement in the clinical setting may
open up the possibility of its application in the future in
determining the expectation of how a particular patient
will respond to infliximab.
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